Synergistic GH release
Co-administration research demonstrates greater GH amplitude than either peptide alone, with sex-stratified pharmacology referenced in mixed-cohort studies.
Hormone
CJC-1295 / Ipamorelin
Synergistic GH research blend
A pre-blended GHRH analog (CJC-1295) and selective GH secretagogue (Ipamorelin) studied together for synergistic pulsatile growth-hormone release.
$69.99per vial · research use
Quantity
Up to 50%
- Synergistic GH pulse research
- Sleep architecture studies
- Recovery & body composition models
For research use only. Not for human consumption.
Women's research notes
What researchers study CJC-1295 / Ipamorelin for in women
Combined GHRH + GHRP research is referenced in women's mid-life studies of sleep quality, body composition, and GH-axis decline that accelerates post-menopause.
Sleep & recovery
Slow-wave sleep, which declines steeply in perimenopause, is a primary endpoint in GH-axis research using this blend.
Body composition
Female pre-clinical models have measured lean mass and adipose redistribution following combined GHRH/GHRP administration.
Selected literature
- Teichman SL, et al. JCEM 2006 — CJC-1295 pharmacokinetics
- Raun K, et al. Eur J Endocrinol 1998 — Ipamorelin, the first selective GH secretagogue
Information below summarizes published pre-clinical and clinical research. It is provided for educational purposes for qualified researchers and is not medical advice, a treatment recommendation, or a claim of efficacy. Products are sold for research use only.
